Artiva details wind-down cost estimates after scrapping AlloNK programNov 9RestructuringArtiva Biotherapeutics, Inc.
Artiva Biotherapeutics halts AlloNK development, cuts staff by 94%Oct 27Quarterly updateArtiva Biotherapeutics, Inc.Biogen
Artiva reports Q2 2026 results, RMAT for AlloNK in refractory RA, Phase 3 planAug 6Quarterly updateArtiva Biotherapeutics, Inc.